Roivant Sciences Ltd. unveiled a new subsidiary – or “vant” as the company calls them – focused on pulmonary conditions. The new company, called Pulmovant, is focused on the development of a potential first-in-class inhaled soluble guanylate cyclase (sGC) activator called mosliciguat for pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Key Takeaways
- Roivant formed a new vant to develop its pulmonary asset mosliciguat; Pulmovant came out of stealth with Phase Ib data on the potentially first-in-class inhaled soluble guanylate cyclase (sGC) activator.
- Mosliciguat is ready to move into Phase II in pulmonary hypertension associated with interstitial lung disease (PH-ILD), a disease area with a greater patient population than PAH but fewer competitors
Roivant announced the launch of Pulmovant on 10 September, coinciding with the release of Phase Ib data on mosliciguat in pulmonary hypertension (PH) at the European Respiratory Society (ERS) Congress in Vienna
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?